The impact of age on pathological insignificant prostate cancer rates in contemporary robot-assisted prostatectomy patients despite active surveillance eligibility.

Journal: Minerva urology and nephrology
Published Date: Aug 1, 2022

Abstract

BACKGROUND: The aim of this study was to assess insignificant prostate cancer (iPCa) rates after robot-assisted radical prostatectomy (RARP) in contemporary patients who were preoperatively eligible for active surveillance (AS). iPCa indicates no risk of PCa progression.

Authors

  • Sami-Ramzi Leyh-Bannurah
    Sami-Ramzi Leyh-Bannurah, Dirk Pehrke, Hartwig Huland, Markus Graefen, and Lars Budäus, Prostate Cancer Center Hamburg-Eppendorf; Sami-Ramzi Leyh-Bannurah, Margit Fisch, and Guido Sauter, University Medical Center Hamburg-Eppendorf, Hamburg; Ulrich Wolffgang, University of Muenster, Muenster, Germany; and Zhe Tian and Pierre I. Karakiewicz, University of Montreal Health Center, Montreal, Canada.
  • Christian Wagner
    St. Antonius-Hospital Gronau, Gronau, Germany.
  • Andreas Schuette
    Department of Urology, Pediatric Urology and Uro-Oncology, St. Antonius-Hospital, Gronau, Germany.
  • Mustapha Addali
  • Nikolaos Liakos
    Department of Urology, Pediatric Urology and Uro-Oncology, St. Antonius-Hospital, Gronau, Germany.
  • Katarina Urbanova
    Department of Urology, Pediatric Urology and Uro-Oncology, St. Antonius-Hospital, Gronau, Germany.
  • Mikolaj Mendrek
    Department of Urology, Pediatric Urology and Uro-Oncology, St. Antonius-Hospital, Gronau, Germany.
  • Matthias Oelke
    Department of Urology, Pediatric Urology and Uro-Oncology, St. Antonius-Hospital, Gronau, Germany.
  • Jörn H Witt

Keywords

External Resources

Popular Topics
Recent Journals